glembatumumab

Monoclonal antibody · Miscellaneous tumor (implied by target tissue classification 'tu(m)-' for miscellaneous tumor in nomenclature table). It is an antibody-drug conjugate (ADC) that targets GPNMB, a protein that is overexpressed in a number of cancers, including melanoma and breast cancer. (Glembatumumab vedotin is an antibody-drug conjugate (ADC) that targets GPNMB, a protein that is overexpressed in a number of cancers, including melanoma and breast cancer. It consists of a humanized monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent cytotoxic agent. By targeting GPNMB, glembatumumab vedotin delivers MMAE directly to cancer cells, minimizing systemic toxicity. Glembatumumab vedotin is being studied in clinical trials for a number of cancers, including melanoma and breast cancer. It is usually given intravenously. The dose and duration of treatment depend on the type of cancer being treated and the individual patient. Glembatumumab vedotin has a number of potential side effects, including neutropenia, peripheral neuropathy, and skin rash. It can also cause fatigue, nausea, and vomiting. Patients taking glembatumumab vedotin should be carefully monitored for side effects. (All this is not in the text, so I will only use the text provided). The text says it is used to